<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429542</url>
  </required_header>
  <id_info>
    <org_study_id>BCA101X1101</org_study_id>
    <nct_id>NCT04429542</nct_id>
  </id_info>
  <brief_title>Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors</brief_title>
  <official_title>First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bicara Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bicara Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound&#xD;
      that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may&#xD;
      exert synergistic activity in patients with EGFR-driven tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A)&#xD;
      followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101&#xD;
      plus pembrolizumab.&#xD;
&#xD;
      The study population in dose escalation (Part A) of single agent BCA101 consists of subjects&#xD;
      with EGFR-driven advanced solid tumors refractory to standard of care or for whom no standard&#xD;
      of care is available. Dose escalation (Part A) of combination BCA101 and pembrolizumab&#xD;
      consists of subjects with either Squamous Cell Carcinoma of the Head and Neck (HNSCC) or&#xD;
      Squamous Cell Carcinoma of the Anal Canal (SCCAC) whose tumors are refractory to standard of&#xD;
      care or for whom no standard of care is available.&#xD;
&#xD;
      Once the maximum tolerated dose (MTD) / recommended dose (RD) of single agent BCA101 is&#xD;
      determined, the study will continue with expansion cohorts (Part B) with select tumor types.&#xD;
      Planned expansion cohorts for single agent BCA101 include 1) PD-L1 negative, EGFR-amplified&#xD;
      Squamous Cell Lung Cancer (SqCLC); 2) RAS wild-type, microsatellite stable Colorectal&#xD;
      Carcinoma (RAS wt, MSS CRC); 3) EGFR-amplified Triple Negative Breast Cancer; and 4) any&#xD;
      solid tumor with either a KRAS G12D or G13D mutation. Planned expansion cohorts for the&#xD;
      combination of BCA101 and pembrolizumab include: 1) HNSCC and 2) SCCAC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and severity of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>21 days</time_frame>
    <description>Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Determine PFS in each part of the study, per RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Determine survival rates in each part of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration vs time profile of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BCA101 and pembrolizumab</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence and titer of anti-drug-antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Squamous Cell Carcinoma of Anal Canal</condition>
  <condition>Uveal Melanoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Chordoma</condition>
  <condition>Squamous Cell Carcinoma of the Lung</condition>
  <condition>EGFR Amplification</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>BCA101 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route: IV Infusion Frequency: QW Dose: 64mg, 240mg, 800mg, 1600mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCA101 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route: IV Infusion Frequency: Q3W Dose: 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCA101</intervention_name>
    <description>EGFR/TGFβ fusion monoclonal antibody</description>
    <arm_group_label>BCA101 + pembrolizumab</arm_group_label>
    <arm_group_label>BCA101 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>anti-PD-1</description>
    <arm_group_label>BCA101 + pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have measurable disease amendable to biopsy and be willing to undergo&#xD;
             both a pre-treatment and on-treatment biopsy, as well as provide archival tumor if&#xD;
             available from the primary tumor (a paraffin embedded tumor tissue block sufficient to&#xD;
             obtain at least 10 sections of 4 to 5 micrometer thickness).&#xD;
&#xD;
          -  Patient must have a performance status of ≤1 on the Eastern Cooperative Oncology Group&#xD;
             Performance Scale.&#xD;
&#xD;
          -  Patients must have evaluable or measurable disease (computed tomography [CT]/magnetic&#xD;
             resonance imaging [MRI] scans performed within 21 days before the screening visit are&#xD;
             acceptable) demonstrating measurable disease, i.e., at least 1 unidimensional&#xD;
             measurable lesion as defined by Response Evaluation Criteria in Solid Tumors, Version&#xD;
             1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST).&#xD;
&#xD;
          -  Tumor eligibility:&#xD;
&#xD;
        PART A (Dose Escalation): Patient must have histologically or cytologically confirmed,&#xD;
        EGFR-driven, advanced solid tumor refractory to current standard of care therapy.&#xD;
&#xD;
        i Single agent BCA101 - patients with the following tumor types will be eligible: 1)&#xD;
        Squamous Cell Lung Cancer (SqCLC) 2) Squamous Cell Carcinoma of the Head and Neck (HNSCC)&#xD;
        3) RAS wild-type microsatellite stable Colorectal Carcinoma (RAS WT MSS CRC) 4) Triple&#xD;
        Negative Breast Cancer (TNBC) 5) Chordoma 6) Squamous Cell Carcinoma of the Anal Canal&#xD;
        (SCCAC) 7) Uveal Melanoma 8) Glioblastoma (GBM) 9) Gastric Cancer 10) Any solid tumor with&#xD;
        a KRAS G12D or G13D mutation 11) Any solid tumor with EGFR amplification 12) Epithelial&#xD;
        Ovarian Cancer 13) Hepatocellular Carcinoma (HCC) 14) Anaplastic Thyroid Cancer (ATC) 15)&#xD;
        Pancreatic Cancer 16) Other EGFR-driven advanced solid tumors (if there is compelling data&#xD;
        or evidence to enroll a patient with a tumor type other than those listed in 1 - 15, the&#xD;
        treating physician may discuss the patient with the Sponsor to determine eligibility). ii.&#xD;
        Combination BCA101 and pembrolizumab - patients with the following tumor types will be&#xD;
        eligible:&#xD;
&#xD;
          1. HNSCC&#xD;
&#xD;
          2. SCCAC&#xD;
&#xD;
        PART B (Cohort expansion): Patients must have histologically or cytologically confirmed&#xD;
        EGFR-driven, advanced solid tumor refractory to current standard of care therapy.&#xD;
&#xD;
        i Single agent BCA101 - patients with the following tumor types will be eligible:&#xD;
&#xD;
          1. PD-L1 negative, EGFR-amplified SqCLC&#xD;
&#xD;
          2. RAS WT MSS CRC&#xD;
&#xD;
          3. EGFR-amplified TNBC&#xD;
&#xD;
          4. Any solid tumor with a KRAS G12D or G13D mutation ii. Combination BCA101 and&#xD;
             pembrolizumab - patients with the following tumor types will be eligible:&#xD;
&#xD;
        1) HNSCC 2) SCCAC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exposure to anti-EGFR antibodies within 4 weeks of the first dose of study drug or any&#xD;
             history of treatment with anti-TGFβ therapies.&#xD;
&#xD;
          -  Prior history of Grade ≥ 2 intolerance or hypersensitivity reaction to cetuximab or&#xD;
             other anti-EGFR therapy or other murine proteins or prior discontinuation of therapy&#xD;
             in the setting of toxicity related to treatment.&#xD;
&#xD;
          -  For Part B only: Prior history of Grade ≥ 2 intolerance or hypersensitivity reaction&#xD;
             to immune checkpoint inhibitors or any history of treatment discontinuation in the&#xD;
             setting of toxicity to an immune checkpoint inhibitor.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Any condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily&#xD;
             of prednisone or equivalent) or other immunosuppressive medication within 14 days&#xD;
             prior to the first dose of study drug, with the exception of topical, intranasal,&#xD;
             intrabronchial, or ocular steroids.&#xD;
&#xD;
          -  Known case of human immunodeficiency virus (HIV), or active hepatitis B (hepatitis B&#xD;
             surface antigen; HBsAg) or hepatitis C.&#xD;
&#xD;
        Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection&#xD;
        (defined as having a negative HBsAg test and a positive antibody to hepatitis B core&#xD;
        antigen [anti HBc] antibody test) are eligible. Patients positive for hepatitis C virus&#xD;
        (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Bohr</last_name>
    <phone>6178000335</phone>
    <email>info@bicara.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber/Partners Cancer Care Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DFCI Clinical Trials Hotline</last_name>
      <phone>877-338-7425</phone>
    </contact>
    <investigator>
      <last_name>Glen Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-608-3759</phone>
    </contact>
    <investigator>
      <last_name>Paul Paik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CPDM Nurse Navigator</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Carvajal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brodeur</last_name>
      <email>brodeurs@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Zanberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilli Neal</last_name>
      <phone>843-792-8113</phone>
      <email>nealli@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carly Fecio</last_name>
      <phone>8437923479</phone>
      <email>fecio@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Kaczmar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beryl Tross</last_name>
      <phone>713-745-0774</phone>
      <email>bmtross@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Van Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18007110500</phone>
    </contact>
    <investigator>
      <last_name>Phillippe Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TGFβ</keyword>
  <keyword>EGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

